Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1(MTM1) polypeptides
The present invention provides chimeric polypeptides comprising myotubularin 1 (MTMI) polypeptides and an internalising moiety, wherein, the moiety can be an antibody, and is preferably monoclonal antibody 3E10, a functional variant or a fragment thereof. One aspect of the present invention provides compositions comprising these chimeric polypeptides together with a pharmaceutically acceptable carrier, and optionally, a further therapeutic agent. Another aspect of the present invention provides methods of treating Myotubular Myopathy comprising administering the polypeptides or compositions comprising the polypeptides to a subject in need.
1. A chimeric polypeptide comprising: (i) a myotubularin (MTM1 ) polypeptide, or a bioactive fragment thereof and (ii) an internalizing moiety,
wherein the chimeric polypeptide has phosphoinositide phosphatase activity;
wherein said internalizing moiety is an antibody or antigen-binding fragment thereof,
wherein said antibody or antigen-binding fragment thereof is a monoclonal antibody 3E10, or a variant thereof that retains the cell penetrating activity of 3E10, or an antibody that binds the same epitope as 3E10, or an antigen-binding fragment of any of the foregoing.
2. The chimeric polypeptide of claim 1 , wherein the MTM1 polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1.
3. The chimeric polypeptide of claim 1 , wherein the MTM1 polypeptide further comprises one or more polypeptide portions that enhance one or more of in vivo stability, in vivo half life, uptake/administration, and/or purification.
4. The chimeric polypeptide of claim 1 , wherein the internalizing moiety promotes transport of said chimeric polypeptide into muscle cells.
5. The chimeric polypeptide of claim 4 , wherein said antibody or antigen-binding fragment thereof is chimeric or humanized.
6. The chimeric polypeptide of claim 4 , wherein said antibody or antigen-binding fragment thereof comprises a light chain comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 4 and a heavy chain comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 2.
7. The chimeric polypeptide of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO: 2 and a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO: 4, or which is a humanized antibody or antigen-binding fragment thereof.
8. The chimeric polypeptide of claim 1 , wherein the internalizing moiety comprises a scFv.
9. The chimeric polypeptide of claim 1 , wherein the MTM1 polypeptide or bioactive fragment thereof is conjugated or joined to the internalizing moiety by a linker.
10. The chimeric polypeptide of claim 9 , wherein the internalizing moiety is conjugated to the N-terminal or C-terminal amino acid of the MTM1 polypeptide.
11. A composition comprising the chimeric polypeptide of claim 1 , and a pharmaceutically acceptable carrier.
12. The composition of claim 11 , further comprising a second agent which acts in an additive or synergistic manner for treating myotubular myopathy.
13. A nucleic acid construct, comprising a nucleotide sequence that encodes the chimeric polypeptide of claim 1 .
14. A nucleic acid construct, comprising a nucleotide sequence that encodes an MTM1 polypeptide or a bioactive fragment thereof, operably linked to a nucleotide sequence that encodes an internalizing moiety,
wherein the nucleic acid construct encodes a chimeric polypeptide having phosphoinositide phosphatase activity;
wherein said internalizing moiety is an antibody or antigen-binding fragment thereof,
wherein said antibody or antigen-binding fragment thereof is a monoclonal antibody 3E10, or a variant thereof that retains the cell penetrating activity of 3E10, or an antibody that binds the same epitope as 3E10, or an antigen-binding fragment of any of the foregoing.
15. The nucleic acid construct of claim 14 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO: 2 and a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO: 4, or which is a humanized antibody or antigen-binding fragment thereof.
16. The nucleic acid construct of claim 14 , wherein the internalizing moiety comprises a scFv.
17. A method of delivering a chimeric polypeptide into a muscle cell, comprising contacting a muscle cell with a chimeric polypeptide, which chimeric polypeptide comprises an MTM1 polypeptide or a bioactive fragment thereof and an internalizing moiety which promotes transport into muscle cells, thereby delivering the chimeric polypeptide into the muscle cell;
wherein said internalizing moiety is an antibody or antigen-binding fragment thereof,
wherein said antibody or antigen-binding fragment thereof is a monoclonal antibody 3E10, or a variant thereof that retains the cell penetrating activity of 3E10, or an antibody that binds the same epitope as 3E10, or an antigen-binding fragment of any of the foregoing.
18. The method of claim 17 , wherein the MTM1 polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1, or a bioactive fragment thereof.
19. The method of claim 17 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO: 2 and a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO: 4, or which is a humanized antibody or antigen-binding fragment thereof.
20. The method of claim 17 , wherein the internalizing moiety comprises a scFv.